Welcome to the website of OXO Translational Science GmbH, located in Wanzleben, Sachsen-Anhalt, Germany.
As a researching pharmaceutical company, we are involved since 1983 in the development, production and marketing of chlorite-based drugs for the treatment of disturbed wound healing and promotion of tissue repair as well as for the therapy of chronic inflammatory diseases, cancer and diabetic vascular diseases.
We are involved since 1983 in the development, production and marketing of drugs used for the treatment of wounds. In Germany the wound healing product is marketed under the name Oxovasin®.
This website contains information to our product Oxovasin® as well as general information on wound healing. Oxovasin® (international tradename: Oxoferin®) is approved in Germany since 1994 for the topical treatment of difficult to heal wounds.
Our company also produces the drug WF10, which, under the tradename Immunokine®, is approved since 2015 in Thailand for the treatment of diabetic foot ulcers (DFU). For further information to this product, please visit the website of the company OXO Chemie Thailand (https://oxothai.com).